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Abstract 
Background: Mass drug administration (MDA) with azithromycin is a cornerstone of the trachoma elimination 
strategy. Although the global prevalence of active trachoma has declined considerably, prevalence persists or even 
increases in some communities and districts. To increase understanding of MDA impact, we investigated the preva‑
lence of active trachoma and ocular C. trachomatis prevalence, organism load, and circulating strains at baseline and 
one‑year post‑MDA in The Gambia and Senegal.
Methods: Pre‑ and one‑year post‑MDA, children aged 0–9 years were examined for clinical signs of trachoma in six 
Gambian and 12 Senegalese villages. Ocular swabs from each child’s right conjunctiva were tested for evidence of 
ocular C. trachomatis infection and organism load (ompA copy number), and ompA and multi‑locus sequence typing 
(MLST) was performed.
Results: A total of 1171 children were examined at baseline and follow‑up in The Gambia. Active trachoma preva‑
lence decreased from 23.9% to 17.7%, whereas ocular C. trachomatis prevalence increased from 3.0% to 3.8%. In 
Senegal, 1613 and 1771 children were examined at baseline and follow‑up, respectively. Active trachoma prevalence 
decreased from 14.9% to 8.0%, whereas ocular C. trachomatis prevalence increased from 1.8% to 3.6%. Higher organ‑
ism load was associated with having active trachoma and severe inflammation. Sequence typing demonstrated that 
all Senegalese samples were genovar A, whereas Gambian samples were a mix of genovars A and B. MLST provided 
evidence of clustering at village and household levels and demonstrated differences of strain variant frequencies in 
Senegal, indicative of an “outbreak”. MLST, including partial ompA typing, provided greater discriminatory power than 
complete ompA typing.
Conclusions: We found that one round of MDA led to an overall decline in active trachoma prevalence but no 
impact on ocular C. trachomatis infection, with heterogeneity observed between villages studied. This could not 
be explained by MDA coverage or number of different circulating strains pre‑ and post‑MDA. The poor correlation 
between active trachoma and infection prevalence supports the need for further work on alternative indicators to 
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Background
Trachoma is the leading infectious cause of blindness 
and targeted for elimination as a public health problem 
by 2020 [1]. Initial infection presents clinically as active 
trachoma [trachomatous inflammation-follicular (TF) 
and/or trachomatous inflammation-intense (TI)]. Years 
of reinfection can lead to scarring of the conjunctiva, 
causing contraction of the eyelid and eyelashes to turn 
inwards to scratch against the eyeball (trichiasis), which 
can result in corneal opacity and blindness. Mass drug 
administration (MDA) with antibiotics is one component 
of the World Health Organization (WHO)-endorsed 
SAFE strategy for trachoma elimination: surgery for tri-
chiasis; antibiotics to clear ocular Chlamydia trachoma-
tis infection; and facial cleanliness and environmental 
improvement to reduce infection transmission [2]. WHO 
recommends MDA, as well as “F” and “E”, at the district 
level (which for trachoma elimination purposes WHO 
defines as “the normal administrative unit for health care 
management consisting of a population unit between 
100,000–250,000 persons”) for five years where TF preva-
lence is ≥ 30% in 1–9 year-olds, three years where TF is 
10.0–29.9%, and one year where TF is 5.0–9.9%, before 
reassessment of TF prevalence [3].
Since 1999, the single oral dose antibiotic, azithromy-
cin, has been donated by its manufacturer, Pfizer, for use 
in SAFE programmes for distribution via the Interna-
tional Trachoma Initiative (ITI). The Gambia and Senegal 
lie in the dry, arid, Sahel belt of West Africa. In The Gam-
bia, evidence from two national surveys carried out in 
1986 and 1996 showed a 54% reduction in the prevalence 
of active trachoma in 0–14 year-olds from 10.4% to 4.9% 
[4]. Subsequent survey data demonstrated 0.3% ocular C. 
trachomatis infection but greater than 10% TF prevalence 
[5], suggesting The Gambia was on course for trachoma 
elimination. However, variation in prevalences between 
communities has also been demonstrated, including as 
a result of re-introduction of infection from untreated 
communities in Senegal [6, 7], which could potentially 
hinder the success of elimination programmes. For Sen-
egal, a national trachoma survey conducted in 2000 esti-
mated that the prevalence of active trachoma in children 
aged under 10 years and not living near Dakar was 10.8% 
[8]. A 2004 study in the Nioro Department (within Kaol-
ack Region, which had a prevalence of 6.8% in the 2000 
survey), had an active trachoma prevalence of 17.4% in 
children aged 2–5 years [9]. These data similarly dem-
onstrated heterogeneity in active trachoma prevalence 
throughout the country.
Randomised controlled trials demonstrate that MDA 
with azithromycin reduces the prevalence of active tra-
choma and ocular C. trachomatis infection in communi-
ties and districts [10, 11]. To date, eight countries have 
been validated as having eliminated trachoma as a public 
health problem by WHO since 2012, and it is projected 
that 70% of formerly endemic districts will have met 
the 5% TF elimination threshold by 2020 [12]. However, 
studies (mainly conducted in medium-high prevalence 
settings) have demonstrated heterogeneous impact of 
MDA, which has potential implications for the success 
of the global effort towards trachoma elimination as a 
public health problem, in reaching and subsequently 
maintaining TF prevalence below the elimination thresh-
old. Some communities experience elimination of active 
trachoma and/or infection, some observe prevalence 
decreases but not to the 5% elimination TF threshold, 
and others encounter rapid re-emergence [13–20]. Expla-
nations for these findings include baseline prevalence of 
active trachoma and/or ocular C. trachomatis infection, 
treatment coverage, re-infection from untreated commu-
nities, random fluctuation, seasonal effects, secular trend, 
and regression to the mean. An additional potential 
explanation is strain diversity. In The Gambia, the num-
ber of strains (as determined by ompA sequence varia-
tion) reduced after MDA, with one strain associated with 
higher organism load [21]. The data did not support the 
hypothesis that ompA polymorphisms were maintained 
within the population by immune selection pressure, 
and it was suggested that typing systems including other 
polymorphic loci could, through greater discrimination, 
help better define ocular C. trachomatis infection popu-
lation dynamics and the impact of MDA. The multi-locus 
sequence typing (MLST) system developed by Klint et al. 
[22] scheme does not exclusively use either short ampli-
cons or housekeeping genes, and provides greater dis-
crimination than ompA alone for genital C. trachomatis 
infection typing [23, 24].
This study, conducted as part of a study evaluating a 
prototype point-of-care test (POCT) for ocular C. tra-
chomatis infection [25], took place before The Gambia 
clinical signs for diagnosing ocular C. trachomatis infection. MLST typing has potential molecular epidemiology utility, 
including better understanding of transmission dynamics, although relationship to whole‑genome sequence vari‑
ability requires further exploration.
Keywords: Active trachoma, Chlamydia trachomatis, Ocular, Mass drug administration, Azithromycin, Prevalence, 
Whole‑genome sequence, Organism load, ompA, Multi locus sequence typing
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had received its azithromycin donation via the ITI, 
whereas MDA of districts in Senegal commenced in 
2005. To understand the reasons for variation in MDA 
impact in these two low prevalence countries at differ-
ent programmatic stages, and since MDA is distributed 
annually, we aimed to investigate the one-year impact of 
a single MDA with azithromycin on active trachoma and 
ocular C. trachomatis prevalence, organism load, circu-
lating strains and spatial distribution in The Gambia (vil-
lages treated in the absence of district-level MDA) and 
Senegal (villages treated as part of MDA of the whole 
district). As a sub-study, we also aimed to evaluate the 
relationship between MLST and whole-genome sequence 
(WGS) variation using a population from Bijagos Islands, 
Guinea-Bissau.
Methods
Field data collection
In The Gambia, six villages in the North Bank and 
Lower River Regions were selected based on previous 
survey data [5] and identified by Community Ophthal-
mic Nurses as having a village prevalence of TF ≥ 10% 
in 1–9 year-old children. These villages met the criteria 
for MDA in 2006 [26] prior to The Gambia receiving its 
azithromycin donation in 2007. In Senegal, the sanitary 
district of Bambey within the medical region of Diour-
bel, which had the highest trachoma prevalence in the 
2000 national survey [8], was identified by the Senega-
lese National Eye Care Programme (NECP) as requiring 
MDA. Prior to MDA, twelve geographically dispersed 
villages under the health post of Keur Samba Kane were 
selected for the study.
Field data collection methods have been described 
in detail elsewhere [25]. Fieldwork in The Gambia took 
place in March–May 2006 (baseline) and June–July 2007 
(one-year follow-up). In Senegal, the baseline study was 
in January–February 2007 and the one-year follow-up 
was in March–May 2008.
At both time-points (baseline and one-year follow-
up), a census of the de facto population was made of the 
selected villages, and global positioning system (GPS) 
coordinates collected for every household using an 
eTrex® H handheld device (Garmin (Europe) Ltd., South-
ampton, UK). In both settings, a household was defined 
as individuals who shared a common cooking pot. After 
written (signature or thumbprint) informed consent 
by their guardians, all children aged 0–9 years were 
examined for clinical signs of trachoma by experienced 
observers using the WHO simplified grading system [27]. 
All the grading was performed by one ophthalmic nurse 
in The Gambia, and another in Senegal. The graders were 
validated using a WHO slide pack and were required to 
achieve a chance corrected agreement (Cohen’s kappa 
statistic [28]) of ≥ 0.8 for TF, TI and TS (trachomatous 
scarring). Two Dacron swabs (Quelab Laboratories, 
Montreal, Canada) were then taken from each child’s 
right upper conjunctiva using a standardised technique 
[29].
Mass drug administration with azithromycin
After examination at baseline, the communities were 
offered MDA with azithromycin. Individuals aged 14 
years and above were given the recommended 1 g of 
azithromycin; children received treatment on the basis 
of 20 mg/kg, using height as a surrogate for weight, up 
to 1 g. Where azithromycin was contra-indicated (chil-
dren aged under 6 months and pregnant women), two 
vials of 1% tetracycline eye ointment were given, with 
instructions on how to apply it. In The Gambia, MDA 
was distributed by the research team in the six study vil-
lages. Individuals who presented themselves who were 
not previously registered on the enumeration form were 
added if they were permanent residents in the household, 
and all were treated. The reason for absence was noted 
for any recorded individual not present during the treat-
ment distribution. In Senegal, treatment of the Bambey 
district was distributed by the Senegalese NECP. Despite 
instructions to the MDA team that a census of household 
members be made before treatment was distributed (the 
study census not being used as MDA was not distributed 
by the research team), only individuals who were given 
treatment were recorded in notebooks. Names from the 
NECP notebooks were matched with the study census to 
calculate treatment coverage.
Detection and copy number estimation of C. trachomatis 
infection
Samples, kept on ice in the field, were transferred to a 
− 20  °C freezer within 10 hours. Chlamydia trachoma-
tis infection was detected in stored samples using the 
Amplicor Chlamydia trachomatis/Neisseria gonorrhoeae 
(CT/NG) Polymerase Chain Reaction (PCR) assay (Roche 
Molecular Systems, Indianapolis, IN, USA) according to 
the manufacturer’s instructions, except that a previously 
published method was used for sample extraction [29]. 
At baseline, the first-collected swab was processed by a 
POCT [25] and the second-collected swab was processed 
by Amplicor. In the one-year follow-up, the first-col-
lected swab was processed by Amplicor and the second-
collected swab was archived. All samples were processed 
within 6 months of collection.
Amplicor-positive samples were purified using the 
QIAamp DNA Minikit 250 (Qiagen, Crawley, UK). 
Two 4 µl replicate samples were each processed in two 
real-time quantitative PCR assays which used a total of 
three primers. The first assay used a genovar A-specific 
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forward primer and a common reverse primer as previ-
ously described [29]. The second assay used the genovar 
B-specific forward primer (5′-TCT gTT gTT gAg TTg 
TAT ACA gAT AC-3′) (Sigma-Genosys, Gillingham, UK) 
with the same common reverse primer.
Gambian sample ompA copy number estimates were 
performed on a LightCycler (Roche Diagnostics, Indian-
apolis, IN, USA). For both genovars, samples were dena-
tured at 95 °C for 15 min. The genovar A samples were 
then subjected to 45 cycles of thermal cycling at 95 °C for 
15 s, 59 °C for 20 s, 72 °C for 15 s, 79 °C for 5 s. The geno-
var B cycling conditions were 45 cycles of 94 °C for 15 
s, 55 °C for 30 s, 72 °C for 30 s, 79 °C for 5 seconds. The 
Senegalese follow-up samples were processed on a Rotor-
Gene RG3000 (Qiagen, Crawley, UK) with the same 
cycling conditions. Samples that did not amplify were 
diluted 1:5, and 1:10 if necessary. The number of ompA 
copies per swab, to represent estimated organism load, 
was estimated using a previously described method [29].
Sequence typing
MLST was performed using the system developed by 
Klint et al. [22] based on the determination of sequences 
at the five loci hctB, CT058, CT144, CT172 and pbpB. 
OmpA and MLST sequencing were attempted on all 
Amplicor-positive Gambian baseline samples, but subse-
quent attempts were limited to samples estimated to con-
tain more than 30 ompA copies/swab. PCR amplification 
and sequencing of the MLST target regions were per-
formed on the Amplicor extract as previously reported 
[23] at the Uppsala University, Sweden. Sequence types 
were assigned profiles using the nomenclature from the 
hr-CT-MLST dataset [30]. Minimum-spanning trees 
were constructed using BioNumerics 7.6 created by 
Applied Maths NV (http://www.appli ed-maths .com).
OmpA amplification and sequencing took place at 
the London School of Hygiene & Tropical Medicine 
(LSHTM), UK. One microliter of the QIAamp purified 
extract was first amplified in a reaction mixture contain-
ing 12.5 µl HotStarTaq master mix (Qiagen, Crawley, 
UK), 4.5 µl of DEPC-treated sterile water, and 1 µl of each 
primer at 12.5 µM. The forward primer (118F: 5′-ATT 
gCT ACA ggA CAT CTT gTC-3′) and reverse primer 
(1163R: 5′-Cgg AAT TgT gCA TTT ACg TgA g-3′) 
(Sigma-Genosys, Gillingham, UK), generated an ampli-
con of approximately 1.28 kb of the ompA gene. The reac-
tion mixture was amplified using a touch-down PCR with 
the following conditions: 95 °C for 15 min; 5 cycles of 94 
°C for 10 s, 63 °C for 30 s and 72 °C for 1 min; 35 cycles of 
94 °C for 10 s, 60 °C for 30 s and 72 °C for 1 min; 72 °C for 
12 min; 4 °C for 30 s; followed by holding at 15 °C.
Sequencing of ompA was performed using primers 
118F and 1163R and inner primers CT2F (5′-TCC AAT 
ATg CTC AAT CTA AAC CTA AA-3′) and CT2R (5′-
TTT Agg TTT AgA TTg AgC ATA TTg gA-3′). Each 
reaction mix contained 2.9 µl DEPC-treated sterile water, 
0.3 µl  BigDye® Terminator v3.1 Ready Reaction Mix and 
2 µl 5× sequencing buffer (Applied Biosystems, Foster 
City, CA, USA), 2 µl primer (at 1.5 µM), and 3 µl ampli-
fied product. The mixture was amplified in 25 cycles of 
96 °C for 10 s, 50 °C for 5 s and 60 °C for 120 s. Amplicons 
were sequenced on a 3730xl sequencer (Applied Biosys-
tems, Foster City, CA, USA). Sequences were analysed 
using Seqscape (ABI, Foster City, CA, USA) and 4Peaks 
(http://meken tosj.com/). Base-calling and assignment of 
quality values were performed using the ‘KB’ Basecaller 
(ABI, Foster City, CA, USA). Mixed bases were called 
when secondary peaks had fluorescence intensity max-
ima greater than 0.65 times that of the corresponding pri-
mary peaks.
Contiguous sequences were aligned against reference 
sequences from A/HAR 13 (GenBank: NC_007429, gen-
ovar A) and B/Jali20/OT (GenBank: NC_012686, genovar 
B). The resulting sequence alignments were trimmed at 
the ends until high quality (Q20) base-calls were present 
at all positions and in all samples. Allele assignments 
were based upon variation within these ‘clear ranges’, 
which were 1092 base-pairs for genovar A and 354 base-
pairs for genovar B.
Sequencing of ompA targeted an extended region 
compared with the hr-CT-MLST dataset [30], therefore 
additional discrimination was achieved for some sam-
ples otherwise considered to be the same sequence type 
(ST). STs separated only by extended ompA genotyping 
were assigned the same ST with an additional alphanu-
meric suffix to indicate discrimination (STs 118d1, 118a1, 
118a2, 118d2, 571, 572).
For the sub-study evaluating the resolution achieved 
between MLST and WGS variation, complete ompA 
typing, WGS and MLST were compared in a popula-
tion from the Bijagos Islands, Guinea-Bissau. A set of 71 
WGS from the Bijagos Islands [31], with inferred MLST 
and ompA types, was utilised to compare these three 
approaches and their utility in epidemiological studies.
Statistical analyses
Results were double-entered and verified in Microsoft 
Access (MS Access v2000/2003XP). Data cleaning and 
analyses were performed in Stata (v9.2, STATA Corp., 
College Station, TX, USA). Population descriptive analy-
ses were conducted, and the immigration rate (Number 
of immigrants (residents only present at follow-up) / 
Total number of residents at follow-up), and emigra-
tion rate (Number of emigrants (residents only present 
at baseline) / Total number of residents at baseline) 
were calculated. GPS data were mapped using ArcGIS 
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9.2 (Environmental Systems Research Institute, Inc. 
Redlands, CA, USA). Statistical significance was deter-
mined at the 5% level. A chi-square test of proportions 
was used to assess active trachoma (TF and/or TI) and 
ocular C. trachomatis infection prevalence data at base-
line and follow-up. Comparison of median organism load 
between baseline and follow-up was performed using a 
non-parametric K-sample test on the equality of medians 
for unmatched data.
MLST analyses are mainly descriptive due to the small 
number of samples and the large number of variants. 
Fisher’s exact test was used to look for intra-country dif-
ferences in variant frequency pre- and post-treatment, 
and to assess the contribution of the six loci to the reso-
lution of strain differences.
For each sample, individual nucleotide sequences at 
the six loci were concatenated and aligned using MUS-
CLE v.3.8 [32]. Genetic (Hamming) distances between 
these concatenates were calculated and plotted using 
PhyML [33]. To determine if there was evidence of geo-
graphical clustering of similar variants, the Hamming 
distances between pairs of samples in the same, and in 
different, cluster strata (village and household) were 
compared using the Mann-Whitney non-parametric test. 
Simulation experiments were carried out in R [34] to test 
whether there was over-representation of short Ham-
ming distances among pairs of geographically related 
samples, and, further and conversely, whether there 
was over-representation of short geographical distances 
between pairs of samples separated by null or short Ham-
ming distances. These experiments were conducted by 
making 10,000 random redistributions of the MLST 
combined with ompA typed samples to their associated 
GPS coordinates.
A numerical index of discriminatory ability was esti-
mated using Hunter & Gaston’s application of Simpson’s 
index of diversity [35]
where N is the number of unrelated strains tested, s the 
number of different types and xj the number of strains 
belonging to the jth type.
D, which takes values between 0 and 1, is the probabil-
ity that two strains randomly chosen from the sample 
will be of different types. Typing methods leading to D 
values of 0.95 or higher are considered highly suitable for 
molecular epidemiology [36].
To infer MLST and ompA types from whole-genome 
sequences, MLST types were determined from filtered 
reads using stringMLST [37] and the  MLST6 (the five 
MLST regions combined with ompA) database [38]. 
D = 1−
1
N (N − 1)
S∑
j=1
xj
(
xj − 1
)
OmpA sequences were extracted from filtered reads by 
aligning to three reference genomes (A/Har13, B/Jali20 
and C/TW3) with Bowtie2 [39], variant calls were identi-
fied with SAMtools/BCFtools [40]. The ompA sequence 
with the lowest percentage-missing calls per whole-
genome sequence was used in downstream analyses.
For phylogenetic analyses,  MLST6 sequences were 
concatenated to create a complete MLST sequence per 
individual. Multiple MLST and genome alignments were 
generated using progressiveMauve. Phylogenies were 
computed using RaxML [41] and visualised in R. MLST 
and WGS phylogenies were compared using R package 
dendextend [42] to determine differences in resolution 
achieved.
Results
Study participation
In The Gambia, 3376 individuals were censused at base-
line, of whom 1289 (38.2%) were children aged 0–9 years. 
At follow-up, 3220 individuals were censused, 1206 
(37.5%) of whom were children. Examination was per-
formed on 1171 of these children at both baseline (90.8%) 
and the one-year follow-up (97.1%). In Senegal, 4822 
(1669 children aged 0–9 years, 34.6%) and 4662 (1807 
children, 38.8%) individuals were censused at baseline 
and follow-up, respectively. Of the children, 1613 (96.6%) 
were examined at baseline and 1771 (98.0%) at follow-
up. A summary of the trachoma indicators, methodol-
ogy, and sample size for each methodology is provided in 
Table 1.
Treatment coverage
In The Gambia, all 3376 baseline community members 
were accounted for as either having received azithro-
mycin, tetracycline eye ointment (TEO), or no treat-
ment. Overall treatment coverage with azithromycin was 
82.0% (84.1% with azithromycin and TEO). In children 
aged 0–9 years, the corresponding figures were 88.8% 
and 88.9% (Fig. 1a). In Senegal, 2444 of the 4822 (50.7%) 
censused community members were not identified in 
the NECP treatment record, resulting in an unknown 
treatment status. This is largely due to no treatment data 
being available for three of the 12 Senegalese villages. The 
overall treatment coverage of the censused population 
was 45.3% with azithromycin (46.2% with azithromycin 
and TEO). For children aged 0–9 years, the correspond-
ing values were 47.0% and 48.3%. If the absolute number 
of individuals treated by the NECP in their notebooks is 
divided by the absolute number of people censused by 
the study team, overall treatment coverage was 82.6% 
(Fig. 1b).
Page 6 of 19Harding‑Esch et al. Parasites Vectors          (2019) 12:497 
One‑year impact of MDA on active trachoma (TF and/or TI) 
prevalence
In The Gambia, the prevalence of active trachoma in 0–9 
year-olds was 23.9% (280/1171; 95% confidence intervals, 
CI: 21.5–26.5%) at baseline and 17.7% (207/1171; 95% CI: 
15.5–20.0%) at follow-up (Table  2, Fig.  1a), represent-
ing a 25.9% decrease. For TF in the 1–9 year age group 
(the indicator and age group used for WHO program-
matic decision-making), the overall and individual vil-
lage TF prevalences continued to surpass the 5% WHO 
threshold for elimination of trachoma as a public health 
problem. However, the follow-up TF prevalence (18.8%, 
196/1042) was significantly lower than that at baseline 
(χ2 = 10.4793, df = 1, P = 0.001). At the village level, the 
prevalence of TF fell in all villages except village 3 where 
it increased marginally from 22.3% to 22.7%.
In Senegal, there was a 46.3% decrease in active 
trachoma prevalence in 0–9 year-olds, from 14.9% 
(240/1613; 95% CI: 13.2–16.7%) at baseline to 8.0% 
(142/1771; 95% CI: 6.8–9.4%) at follow-up (Table  2, 
Fig.  1b). In Senegal, the overall TF prevalence in 1–9 
year-olds (8.2%, 133/1619) fell below the 5% thresh-
old, and was significantly lower than at baseline (χ2 = 
26.9905, df = 1, P < 0.001). Compared with baseline, the 
prevalence of TF decreased in all villages except in vil-
lages 1, 6, and 11. Only 4 villages had a prevalence above 
10% at follow-up: villages 1 (15.4%), 3 (14.2%), 6 (15.4%) 
and 11 (24.6%).
One‑year impact of MDA on ocular C. trachomatis infection 
prevalence
In The Gambia, 3.0% (35/1171; 95% CI: 2.1–4.1%) of chil-
dren aged 0–9 years-old were Amplicor-positive at base-
line compared with 3.8% (45/1171; 95% CI: 2.8–5.1%) at 
follow-up (Table 2, Fig. 1a); a 26.7% increase. At the vil-
lage level, the prevalence fell in four villages, two of which 
had no infection and the other two only having one case 
of infection at follow-up. The prevalence increased in two 
villages: village 1 (6.4 vs 6.9%, χ2 = 0.0313, df = 1, P = 
0.860) and village 5 (3.2 vs 9.0%, χ2 = 9.5139, df = 1, P = 
0.002). Treatment coverage was low in village 1 (53.0%), 
but high in village 5 (95.4%) (Fig. 1a).
In Senegal, 1.8% (29/1613; 95% CI: 1.2–2.6%) of chil-
dren aged 0–9 years-old were Amplicor-positive at base-
line compared with 3.6% (64/1771; 95% CI: 2.8–4.6%) at 
follow-up (Table 2, Fig. 1b), representing a 100% increase. 
At the village level, the prevalence of Amplicor-positives 
stayed the same at 0% in four villages, fell in three vil-
lages, and increased in five (Fig. 1b).
Change in active trachoma and ocular C. trachomatis 
infection for children present at both time‑points
Approximately 80% of the village population was pre-
sent at both time-points, for both countries (Table 3). In 
The Gambia, 847 censused children were present at both 
time-points. The immigration rate was 0.14, and the emi-
gration rate was 0.18. In Senegal, 1282 censused children 
Table 1 Summary of the trachoma indicators, methodology, and sample size
Abbreviations: na, not applicable;TF, trachomatous inflammation‑follicular; TI, trachomatous inflammation‑intense; PCR, polymerase chain reaction
Trachoma indicator Methodology Sample size (children aged 0–9 years) Total
The Gambia Senegal
Baseline
(March–
May 
2006)
One year 
follow‑up
(June–
July 2007)
Baseline
(January–
February 
2007)
One year 
follow‑up
(March–
May 
2008)
Children aged 0–9 years examined 
for active trachoma (TF and/or TI)
WHO simplified grading system [27] 1171 1171 1613 1771 5726
Ocular C. trachomatis infection Amplicor PCR (Roche Molecular Systems) 1171 1171 1613 1771 5726
Organism load of Amplicor‑positives ompA copy number estimates using two real‑time quan‑
titative PCR assays for genovars A and B separately [29]
35 45 29 64 173
Multi‑locus sequence typing (MLST) Determination of sequences at the five loci: hctB, CT058, 
CT144, CT172, pbpB [22, 23]
13 18 13 29 73
ompA sequencing Sequences aligned against reference sequences from 
A/HAR 13 (NC_007429, genovar A) and B/Jali20/OT 
(NC_012686, genovar B), with alignments trimmed 
at the ends until high quality (Q20) base‑calls were 
present at all positions
19 21 16 38 94
MLST6 The five MLST regions combined with ompA 14 18 12 28 72
Whole‑genome sequencing (WGS) Set of 71 WGS from the Bijagos Islands with inferred 
MLST and ompA types [40]
na na na na 71
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were present at both time-points. The immigration and 
emigration rates were 0.16 and 0.19, respectively.
In The Gambia, of those who had active trachoma at 
baseline, 39.0% (82/210) had active trachoma at follow-
up indicating that clinical signs resolved in 61.0% of 
children (Table 3). There was evidence of development 
of active trachoma between baseline and follow-up. Of 
all children present at both baseline and follow-up, 7.8% 
(66/847) developed active trachoma between baseline 
and follow-up, and 3.2% (27/847) became infected. Of 
those infected at any time-point, 14.5% (8/55) devel-
oped active trachoma between baseline and follow-up, 
whereas 7.3% (58/792) of children with no infection at 
either time-point developed active trachoma between 
baseline and follow-up. There was little evidence to 
suggest that those with infection at any time-point 
were significantly more likely to have developed active 
trachoma at follow-up than those without infection (χ2 
= 3.7335, df = 1, P = 0.053). Of 28 children infected 
at baseline, 7 (25%) were also infected at follow-up. Of 
these, six were above the baseline median load of 405 
ompA copies/swab: 4; 6317; 20,127; 62,131; 174,155; 
185,246; and 318,918 ompA copies/swab (Table 4). 0.8% 
of 0 year-olds at follow-up (and therefore untreated) 
were Amplicor-positive.
In Senegal, of those who had active trachoma at base-
line, 25.2% (53/210) had active trachoma at follow-up, 
which indicates that clinical signs resolved in 74.8% of 
children by follow-up (Table 3). Of all children present 
at both baseline and follow-up, 4.6% (59/1282) devel-
oped active trachoma between baseline and follow-
up, and 3.4% (43/1282) became Amplicor-positive. Of 
the 69 children with ocular C. trachomatis infection at 
any time-point, 29.0% (20/69) of children had devel-
oped active trachoma between baseline and follow-up. 
Of 1213 children not infected at either time-point, 39 
(3.2%) developed active trachoma between baseline and 
follow-up. Those with infection at either time-point 
Fig. 1 Prevalence of active trachoma (TF and/or TI) and ocular C. trachomatis infection in 0–9 year‑olds at baseline and follow‑up in relation to 
azithromycin treatment coverage in The Gambia and Senegal
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were significantly more likely to develop active tra-
choma between baseline and infection than those with-
out infection (χ2 = 98.7551, df = 1, P < 0.001). Similar 
to the Gambian results, all but one of these were above 
the baseline median load of 2730 ompA copies/swab: 
4268; 27,653; 46,823; 50,293; and 125,626 ompA cop-
ies/swab (Table 4). Of the 0 year-olds at follow-up, 4.0% 
were Amplicor-positive.
Concordance between active trachoma (TF and/or TI) 
and ocular C. trachomatis infection
The difference between overall active trachoma and 
Amplicor-positive prevalence was significant in both 
countries at both baseline and follow-up (Gambia base-
line: χ2 = 39.5518, df = 1, P < 0.001; Gambia follow-
up: χ2 = 70.3365, df = 1, P < 0.001; Senegal baseline: χ2 
= 107.4340, df = 1, P < 0.001; Senegal follow-up: χ2 = 
252.1291, df = 1, P < 0.001). At baseline, only approxi-
mately 10% of children with active trachoma were Ampli-
cor-positive in both countries (Table  2), whereas 68.6% 
(The Gambia) and 82.8% (Senegal) of Amplicor-positives 
had active trachoma. At follow-up, 14.0% and 27.5% of 
those with active trachoma were Amplicor-positive in 
The Gambia and Senegal, respectively. Approximately 
60% of those who were Amplicor-positive had active 
trachoma in both countries (Table  2). The relationship 
between active trachoma and infection did not change 
between time-points, except for Senegal where there 
was evidence (Z = 2.1, P = 0.0364) that the decrease in 
proportion of those infected also having active trachoma 
was significantly lower at follow-up than at baseline in 
Senegal.
One‑year impact of MDA on organism load
For both countries and time-points, the organism load of 
Amplicor-positive children was lower for those who were 
clinically normal, than for those with active trachoma 
(Table  4). In The Gambia, the overall median organ-
ism load at baseline was 405 ompA copies/swab, com-
pared with 22 copies/swab at follow-up (K-sample test: 
P = 1.000). However, median organism load increased 
between baseline (1556 copies/swab) and follow-up (8133 
copies/swab) for those with active trachoma (K-sample 
test: P = 0.785). In Senegal, the median load was higher 
at follow-up than at baseline, both overall (5855 vs 2,730, 
P = 0.180) and for those with active trachoma (13,260 vs 
4670; K-sample test: P = 0.439).
Table 3 Clinical and Amplicor result status comparison between baseline and follow‑up for children present at both time‑points
Active trachoma (TF and/or TI) Amplicor‑negative at 
both time‑points
Amplicor‑positive at 
both time‑points
Amplicor‑positive 
at baseline only
Amplicor‑positive 
at follow‑up only
Total
The Gambia No active trachoma at either time‑point 552 0 6 13 571
Active trachoma at both time‑points 68 6 1 7 82
Active trachoma at baseline only 114 0 13 1 128
Active trachoma at follow‑up only 58 1 1 6 66
Total 792 7 21 27 847
Senegal No active trachoma at either time‑point 995 0 4 14 1013
Active trachoma at both time‑points 38 5 1 9 53
Active trachoma at baseline only 141 0 16 0 157
Active trachoma at follow‑up only 39 0 0 20 59
Total 1213 5 21 43 1282
Table 4 Median estimated organism load (ompA copies/swab) by clinical status of Amplicor‑positive children
a All those with active trachoma (TF and/or TI) had trachomatous inflammation‑follicular (TF)
Abbreviation: na, not applicable
Clinical status Gambian baseline Gambian follow‑up Senegalese baseline Senegalese follow‑up
n Median Range n Median Range n Median Range n Median Range
Normal 11 5 4–26 16 4 4–12,510 5 5 4–604 25 4 4–119,344
Active  trachomaa 24 1556 4–3,008,063 29 8133 4–6,300,075 24 4670 4–174,507 39 13,260 4–564,558
Any TI 0 na na 3 1252 4–1,899,670 4 48,558 3071–126,749 6 58,702 2920–564,558
Overall 35 405 4–3,002,063 45 22 4–6,300,075 29 2730 4–174,507 64 5855 4–564,558
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One‑year impact of MDA on circulating strains
Sequence was more likely to be recovered from samples 
with high ompA copy number estimates. Samples suc-
cessfully sequenced for the five MLST regions contained 
a median of 44,952 ompA copies/swab, compared to 1142 
ompA copies/swab where sequencing was incomplete 
or unsuccessful. Sequencing was not attempted where 
organism load was less than 30 ompA copies/swab or 
where there was no sample left. MLST sequencing was 
attempted on 99 (57.2%) of the 173 Amplicor-positive 
samples, resulting in 26 incomplete sequences and 73 
complete sequences (Table  1). OmpA sequencing was 
attempted on 128 (74.0%) samples, successfully for 94 
(73.4%) samples (Table  1). 72 (41.6%) Amplicor-positive 
samples were fully sequenced for  MLST6 (the five MLST 
regions combined with ompA) (Table 1).
Samples from Senegal yielded exclusively genovar A 
sequences. In The Gambia, eight of 14 (57.1%) ompA 
sequences at baseline, and 13 of 18 (72.2%) of ompA 
sequences from follow-up samples, were genovar A with 
the rest genovar B.
For each of ompA, MLST and  MLST6, both com-
mon and country-specific variants were present at both 
baseline and follow-up (Fig.  2). In Senegal, there was a 
decrease in the number of variants at follow-up, with one 
new variant appearing (119a) in Senegalese village S-03 
(Fig. 3b). Variant 119a was closely related to 119b, which 
was also present at follow-up (Fig.  4). In Gambian vil-
lage G-01, new variants 118d2, 125 and 571 joined vari-
ants 120 and 118d1 present at baseline. Figure 4 suggests 
that 125 is closely related to 120, 118d2 is closely related 
to 118d1, and 571 lies on its own branch. There was no 
evidence of a significant difference in variant frequency 
between baseline and follow-up in The Gambia (Fig. 2). 
In contrast, the frequency of ompA, hctB, CT144, and 
 MLST6 variants differed significantly between baseline 
and follow-up in Senegal (Fisher’s exact test: P < 0.001). 
These differences are due to one variant (119b) that 
only featured once in 16 samples at baseline (8.3%), but 
accounted for 24 (85.7%) of the 28 samples at follow-up. 
This “outbreak” at follow-up is depicted in Fig. 3a. Mixed 
infections, which would have been indicated by mixed 
base calls in both directions of the sequencing, were not 
detected.  
For both ompA (n = 94) and  MLST6 (n = 72) types, in 
both countries and at both time-points, there was a sig-
nificant over-representation of short genetic distances in 
sample pairs derived from the same, rather than different, 
villages, indicating that similar strains tended to cluster 
in villages (Table  5). Similarly, at household level, there 
Fig. 2 MLST6 variant frequency in The Gambia and Senegal before and one year after mass drug administration with azithromycin.  MLST6 variants 
include ompA combined with all five  MLST5 regions (hctB, CT058, CT144, CT172, pbpB)
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Fig. 3 Geographical location of variants in Senegalese villages before and one year after mass drug administration with azithromycin. a Senegalese 
villages 6 and 11: “outbreak” of variant 119b at follow‑up. b Senegalese village 3: variants 119b and 119a appeared at follow‑up. Variant 47b 
remained in one household at follow‑up, whereas the other variants disappeared between baseline and follow‑up
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was evidence of significant clustering of similar ompA 
and  MLST6 types at follow-up in both countries.
Simulation experiments suggested that at both time-
points there was an over-representation of short genetic 
distances among sample pairs that were geographically 
close (e.g. < 5 km) (P < 0.001) and conversely that short 
geographical separations were over-represented among 
sample pairs that were genetically similar (e.g. to less 
than three base substitutions) (P < 0.01).
Fig. 4 Phylogenetic relationships between the  MLST6 variants. Bootstrap confidence values are shown at branch‑points. Genotype: unique number 
of variant super‑type; village: all villages have been coded. Senegalese villages are prefixed with an “S”, and Gambian villages prefixed with a “G”
Table 5 P‑values for evidence of clustering at different cluster strata. Analyses based on comparisons of genetic distances between 
pairs of participants, based on the Hamming distance for pairs of participants in same or different cluster strata
Note:  MLST6 variants include ompA combined with all five  MLST5 regions (hctB, CT058, CT144, CT172, pbpB)
Cluster strata The Gambia Senegal
ompA MLST6 ompA MLST6
Baseline Follow‑up Baseline Follow‑up Baseline Follow‑up Baseline Follow‑up
Village < 0.001 < 0.001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
Household 0.156 < 0.002 0.37 0.03 0.229 < 0.0001 0.039 0.0029
Page 13 of 19Harding‑Esch et al. Parasites Vectors          (2019) 12:497 
Comparing MLST, complete ompA typing and WGS
In the sub-study comparing resolution achieved between 
WGS, ompA and MLST in a set of 71 WGS from Bijagos 
Islands, Guinea-Bissau [31], MLST discriminatory index 
was higher for the samples in this study compared with 
the Guinea-Bissau population (D = 0.825 vs D = 0.743), 
neither had discriminatory power considered to be nec-
essary for molecular epidemiology (D = 0.95). Minimum 
spanning tree (MST) analyses showed minimal sharing 
of STs between these studies; however, STs from these 
studies did form overlapping clusters (Fig. 5). Equivalent 
sample size, MLST discriminatory power and clustering 
of STs support the population from Guinea-Bissau as a 
sensible comparator to this study.
MLST6, including partial typing of ompA, identified 
12 STs in Guinea-Bissau (D = 0.743). Inference of full-
length ompA from WGS identified 20 variants, with a 
discriminatory index of (D = 0.8805). All WGS were 
unique. Grouping WGS with < 401 SNPs between them 
(fifth percentile of all pairwise differences) identified 35 
‘WGS-types’, with a discriminatory index between MLST 
and ompA (D = 0.765). MST analyses of STs with isolates 
coloured by ompA type (Fig. 6a) or WGS-type (Fig. 6b) 
showed increased resolution using either method, and 
poor correlation with STs. Comparison of phylogenetic 
relationship between samples corroborated the disparity 
between WGS and STs (Additional file 1: Figure S1).
Phylogenetic analysis of WGS from Guinea-Bissau 
showed clustering by village of collection, supporting the 
utility of WGS for molecular epidemiology. MST analy-
ses of STs with isolates coloured by village of collection 
showed evidence of clustering by village, however 6/12 
STs were identified in multiple villages (Fig. 7).
Discussion
In this study, we assessed the one-year impact of MDA 
with azithromycin in six Gambian and 12 Senegalese vil-
lages. Overall, active trachoma prevalence decreased in 
both countries. Conversely, there was no impact on ocu-
lar C. trachomatis infection, with an increase in preva-
lence observed in Senegal. There was a poor correlation 
between having active trachoma and being Amplicor-
positive, whilst having higher organism load was asso-
ciated with having active trachoma and more severe 
inflammation (TI). All Senegalese samples were genovar 
A, whereas The Gambia presented a mix of genovar A 
and B samples. MLST results demonstrated differences 
in number of circulating strains in Senegal but not in The 
Fig. 5 Minimum spanning tree analysis of publicly available ocular C. trachomatis isolates based on the six MLST target regions visualised by 
isolate origin. Sphere sizes indicate the numbers of samples in each sphere. Solid branches show single‑locus variants, dashed branches show 
double‑locus variants and dotted branches show triple‑locus variants. All publicly available ocular C. trachomatis isolates were included in the 
analyses
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Gambia, and also provided evidence of clustering at vil-
lage and household levels.
There were some methodological differences between 
baseline and follow-up: at baseline, the Amplicor results 
came from the second-collected swab (the first-collected 
swab was processed by a POCT [25]), whereas at follow-
up, Amplicor was performed on the first-collected swab. 
This could have affected the prevalence of infection 
observed at baseline, as the first-collected swab may have 
a higher load of infection than the second [43]. However, 
comparison between first- and second-collected swab 
results by others, and within this study (data not shown), 
has demonstrated excellent concordance [44, 45], unsur-
prising as the detection level of Amplicor is in the range 
of 1–10 elementary bodies [46, 47]. Another limitation is 
that the grader training did not follow the current glob-
ally standardised training system, which includes field-
based inter-grader agreement (IGA) assessments because 
grading projected slides is not equivalent to field grading 
[48]. We did, however, attempt to validate grader exami-
nation. In The Gambia, a third grader (RLB) returned to 
some of the villages and verified with success the cases 
identified as clinically active. In Senegal, at the one-year 
follow-up, 50 sequential children were double-graded by 
both the Senegalese and Gambian ophthalmic nurses, 
once towards the beginning and once towards the end of 
the fieldwork, with each grader blind to the other’s diag-
nosis. For the first exercise, the kappa score was 0.8649, 
with an expected agreement of 70.40% and an observed 
agreement of 96.00%, showing almost perfect agreement. 
For the second exercise, the kappa score was 0.5524, with 
an expected agreement of 68.72% and an observed agree-
ment of 86.00%, demonstrating moderate agreement, 
with the Senegalese grader tending to over-diagnose 
active trachoma compared with the Gambian grader. Fur-
thermore, the graders knew that the villages had received 
MDA, which could have biased the graders to under-esti-
mate the active trachoma prevalence. However, given the 
one-year follow-up results (all Gambian villages and four 
Senegalese villages with > 5% TF in 1–9 year-olds), com-
bined with the grader validation exercises, any such bias 
seems to have had a minimal effect on overall results.
As no control villages were included in this study to 
compare what would have happened in the absence of 
MDA, the active trachoma prevalence declines observed 
cannot be attributed to MDA alone. The results could be 
due to random fluctuation, seasonal effects or regression 
to the mean of the villages as these communities were 
Fig. 6 Minimum spanning tree analysis of ocular C. trachomatis isolates from the Bijagos Islands, Guinea‑Bissau based on the six MLST target 
regions visualised by ompA type (a) and ‘WGS‑type’ (b). Sphere sizes indicate the numbers of samples in each sphere. Solid branches show 
single‑locus variants, dashed branches show double‑locus variants and dotted branches show triple‑locus variants. WGS with < 401 SNPs between 
them (fifth percentile of all pairwise differences) were defined as a ‘WGS‑type’
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chosen to have a sufficiently high prevalence of disease 
to qualify them for MDA. Regression to the mean may 
reduce infection over time even without treatment [49]. 
Secular trend is another plausible explanation with stud-
ies showing that active trachoma can disappear in the 
absence of trachoma control programmes [50–53].
Our results question the reliance upon clinical signs to 
make decisions regarding implementing trachoma elimi-
nation measures. The WHO active trachoma indicator 
for programmatic decisions regarding MDA initiation 
and duration is the prevalence of TF in children aged 1–9 
years. TF was a poor predictor for infection, but infection 
was a fairly reliable indicator for having TF, consistent 
with others’ findings in low prevalence or mass treated 
settings [7, 15, 44, 54–61]. Furthermore, our data indicate 
that the assertion by others that inclusion of TI would 
improve the association between clinical signs and infec-
tion [62] is likely context-specific. Of infected individuals, 
those with active trachoma (TF and/or TI) or “any TI” 
had a higher load of infection than those without disease. 
Furthermore, in Senegal, those with “any TI” had higher 
loads than those with active trachoma, demonstrating 
higher loads with increasing severity of inflammation, 
as previously noted in West Africa [7, 63]. Thus, high 
chlamydial load was a good marker for disease status, but 
active trachoma remained a poor predictor of infection. 
These data support the continued need for further work 
developing alternative indicators for diagnosing ocular C. 
trachomatis infection, as reliance on clinical signs is both 
poorly sensitive and specific [25, 64].
After one round of MDA, TF prevalence in 1–9 year-
olds did not fall below the WHO 5% threshold for elimi-
nation of trachoma as a public health problem in any of 
The Gambia villages, and only in four of the Senegalese 
villages. This is expected, as the WHO recommendation 
is for three years of MDA before reassessment where TF 
prevalence is 10-29.9% [65]. Overall treatment coverage 
was above the WHO recommended minimum level of 
80% [66] in The Gambia (data from Senegal were unre-
liable). However, at a village level, meeting the 80% tar-
get was not always consistent with favourable impact on 
active trachoma and infection prevalence. Despite others 
having demonstrated that a single MDA round with high 
coverage can be effective [13, 17], our results support the 
importance of implementation of the whole SAFE strat-
egy, as high MDA coverage alone is not sufficient for 
reducing and sustaining trachoma prevalence to below 
the elimination threshold [12]. The lack of impact on 
infection indicates transmission continued to occur post-
MDA. This indication of continued transmission is sup-
ported by the development of active trachoma and ocular 
C. trachomatis infection in children present at both base-
line and follow-up in both countries, the appearance of 
new strains as determined by MLST at follow-up, and 
the observation that some children aged under one year 
at follow-up (and therefore untreated) had both evidence 
of infection and active trachoma. Of children infected at 
baseline still infected at follow-up, all but one had organ-
ism loads above the median at baseline, supporting oth-
ers’ findings that those with high loads at baseline who 
receive treatment are more likely to be infected at follow-
up [29, 63, 67]. We observed that approximately 20% of 
the population at follow-up was not present at baseline 
for both countries. Re-infection from migration (includ-
ing into The Gambia from Senegal) has previously been 
reported [16, 68, 69]. This further highlights the impor-
tance of investing in the long-term “F” and “E” compo-
nents of the SAFE strategy to limit transmission.
A proposed explanation for the success of MDA, 
despite the risk of outside re-infection, is the “Allee 
effect”, a concept taken from population biology [49]. It 
has been proposed that a variety of immunotypes allows 
Fig. 7 Minimum spanning tree analysis of ocular C. trachomatis 
isolates from the Bijagos Islands, Guinea‑Bissau based on the six 
MLST target regions visualised by village of collection. Sphere sizes 
indicate the numbers of samples in each sphere. Solid branches show 
single‑locus variants, dashed branches show double‑locus variants 
and dotted branches show triple‑locus variants
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Chlamydia to better evade the human immune response, 
and that if the effect of MDA was to reduce the diversity 
of chlamydial strains, the prevalence of infection may 
not be able to return to previous levels [49]. The differ-
ence in the effect of MDA between the communities may 
therefore be due to the variety of immunotypes circulat-
ing. The MLST system enabled us to identify a number 
of different circulating strains in both countries, at both 
time-points. In Senegal, we observed a reduction in 
strain diversity following MDA, similar to that observed 
with ompA types in The Gambia previously [21]. The 
reduction in diversity in Senegal only may possibly reflect 
the simultaneous MDA of the district compared to the 
treatment of isolated villages independently of their sur-
rounding settlements in The Gambia, which may have 
increased vulnerability to re-infection. The reduction 
in diversity in Senegal, is however inconsistent with the 
Allee effect hypothesis, since an increase in overall ocular 
C. trachomatis prevalence was observed at follow-up.
Different typing schemes have been developed and 
implemented, and have been interpreted as providing 
evidence of intra-familial transmission of trachoma [21, 
54, 70–72], and of clustering of related trachoma infec-
tions at the household level [73, 74]. OmpA genotyping 
has also suggested that some individuals may be persis-
tently infected with the same strain [70, 71, 75], and that 
recombination and mixed infections both occur [76–78]. 
In genital C. trachomatis infections, MLST has a consid-
erably higher discriminatory capacity than ompA typing 
[79, 80] and was therefore used in this study to investi-
gate its usefulness in trachoma surveillance. We addi-
tionally evaluated the relationship between MLST and 
whole-genome sequence variation as a sub-study, using a 
population from Bijagos Islands, Guinea-Bissau.
MLST provided evidence that some individuals 
infected at both time-points were re-infected rather 
than persistently infected, and suggested that a single 
re-infecting strain (119b) had spread widely in a Sen-
egalese village. We also noted geographical clustering of 
genetically similar strains, which is reassuring in that it is 
consistent with the generally accepted notion that most 
individuals acquire ocular C. trachomatis infection from 
members of the same household or community [63, 67]. 
However, almost 60% of the ocular infections we found 
could not be fully typed, restricting the amount of data 
for comparisons. The types that we successfully deter-
mined are biased towards the samples containing more 
ompA copies. This, independently of the discrimina-
tory ability of the typing itself, further reduces its utility 
for molecular epidemiology and precludes the analysis 
of some key questions such as whether strains vary in 
their transmissibility or in their tendency to cause ocu-
lar inflammation or disease sequelae. We previously 
reported distinct strain types associated with variation 
in sample ompA copy number [21], but if that had been 
the case in this study, we would not have detected it. 
The typing scheme proved quite demanding of sample, 
with some samples being used up entirely. These prob-
lems may be overcome in future by the development and 
incorporation of array-based typing methods into the 
 MLST6 scheme [81].
The sub-study comparing WGS and MLST in a popu-
lation from Bijagos Islands, Guinea-Bissau highlighted 
the improved resolution achieved with WGS. MST and 
phylogenetic analyses also identified considerable dis-
crepancy in the relatedness of isolates between WGS 
and MLST. WGS of C. trachomatis is possible directly 
from clinical samples with as few as 500 genome cop-
ies [31, 82–84]. However, it is still relatively expensive 
compared to MLST. Applying Simpson’s discriminatory 
index to WGS produced a value of zero. Even attempts 
to define ‘WGS-types’ produced a lower discriminatory 
index than ompA typing. This is due to the high preva-
lence of unique isolates and ‘WGS-types’, respectively, 
which are discounted when calculating the index. MLST, 
including partial ompA typing, provided greater discrimi-
natory power than complete ompA typing in this study. 
The opposite was true for inferred MLST and ompA 
types from Guinea-Bissau. The inconsistency of the low 
discriminatory power of MLST in ocular C. trachomatis 
and the increased resolution of WGS, suggests that novel 
targets are required if MLST is to be utilised in studies of 
trachoma.
In addition to overcoming these methodological chal-
lenges of MLST, to better understand the impact of MDA 
on active trachoma and ocular C. trachomatis infec-
tion, it would be helpful to have longer follow-up and 
the inclusion of control villages. Additional information, 
such as on travel patterns in both The Gambia and Sen-
egal, could help understand the contribution of imported 
infection on long-term active trachoma and infection 
prevalence, circulating strains, and ultimately the success 
of trachoma elimination programme interventions.
Conclusions
We found that one round of MDA with azithromycin 
led to an overall decline in active trachoma prevalence 
but no impact on ocular C. trachomatis infection, with 
heterogeneity between the villages studied. The poor 
correlation between active trachoma and infection preva-
lence supports the need for further work on alternative 
indicators to clinical signs for diagnosing ocular C. tra-
chomatis infection. The use of MLST typing has potential 
molecular epidemiology utility, including better under-
standing of transmission dynamics, although relationship 
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to whole-genome sequence variability requires further 
exploration.
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